Clinical trials: Butylphthalide
Moyamoya Disease, Ischemic Cerebral Infarction
NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events
An extracranial-to-intracranial (EC-IC) revascularization is the most widely used treatment to improve cerebral perfusion in patients with moyamoya disease (MMD), and it has been shown to reduce the risk of subsequent stroke and…
- Conditions
- Moyamoya Disease, Ischemic Cerebral Infarction, Ischemic Stroke, Ischemic Cerebrovascular Accident
- Trial name
- NICE-MMD (NCT04205578)
- Testing
- dl-3-n-butylphthalide (NBP), Normal Saline 0.9% Infusion Solution
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- yuanli Zhao
Butylphthalide, Cardiac Arrest
Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients
Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die.
- Conditions
- Butylphthalide, Cardiac Arrest, Neuroprotective Drugs
- Trial name
- NCT06572085
- Testing
- Butylphthalide and Sodium Chloride Injection, Saline Solution
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Tang Ziren
Stroke, Lacunar, Stroke, Acute Ischemic
Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)
The goal of this multicenter, double-blind, 2×2 factorial randomized controlled trial is to evaluate the efficacy and safety of isosorbide mononitrate, butylphthalide, and their combination in reducing disability in patients with…
- Conditions
- Stroke, Lacunar, Stroke, Acute Ischemic, Cerebral Small Vessel Diseases
- Trial name
- NCT07252544
- Testing
- Isosorbide Mononitrate, Butylphthalide
- Volunteers
- 3,156 people
- Sponsor
- Beijing Tiantan Hospital
Focal Epilepsy, Cognitive Impairment
Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
This is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of butylphthalide soft capsules for treating cognitive impairment in elderly patients with focal epilepsy.
- Trial name
- NCT07193277
- Testing
- Butylphthalide
- Where
- China
- Volunteers
- 220 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Subcortical Vascular Dementia, Cerebral Small Vessel Diseases
The Efficacy of DL-NBP in Patients With Mild Subcortical Ischemic Vascular Dementia
This is a 48-week, double-blind, randomized, placebo-controlled study. Sixty-four patients are randomly assigned to take NBP (600mg per day) or placebo for 48 weeks, with 32 patients in each treatment group.
- Trial name
- NCT03906123
- Testing
- NBP
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Tianjin Medical University General Hospital
Stroke, Post-stroke Cognitive Impairment (PSCI)
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
Post-stroke cognitive impairment (PSCI) refers to a clinical syndrome characterized by cognitive impairment that occurs after a stroke event and persists for at least 24 weeks.
- Trial name
- Be-CLEVER (NCT05976152)
- Testing
- dl-3-butylphthalide
- Where
- China
- Volunteers
- 3,200 people
- Sponsor
- Fudan University
Mild Disabling Acute Ischemic Stroke
Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke
Abstract Background Intravenous thrombolysis is the cornerstone of early treatment for acute ischemic stroke (AIS), but some still have a poor prognosis, especially in patients with mild disabling stroke.
- Trial name
- BENEFIT-2 (NCT07369999)
- Testing
- Combination Group, Control Group
- Where
- 15 sites in China
- Volunteers
- 1,062 people
- Sponsor
- Xiangya Hospital of Central South University
Acute Ischemic Stroke
Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke
The primary objective of this study is to compare effectiveness of five different neuroprotectants, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.
- Trial name
- CER (NCT01556854)
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- yongjun wang
AIS
NBP in Adult Patients With Acute Ischemic Stroke (AIS)
This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on to standard of care study of NBP softgel capsules for the treatment of mild to moderate AIS in adults.
- Trial name
- NCT02905565
- Testing
- NBP Softgel Capsules
- Where
- 21 sites in United States
- Volunteers
- 177 people
- Sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.
Restenosis
Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting
The purpose of this study is to determine whether butylphthalide are effective for Preventing Restenosis after Intracranial and Extracranial Artery Stenting
- Trial name
- BPRIAS (NCT01405248)
- Testing
- Butylphthalide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jinling Hospital, China
Stroke, Cerebral Infarction
For Patients With Ischemic Stroke, Clinically Study the Effectiveness and Safety of Butylphthalide.
This is a prospective, open, single-arm, the real world of clinical trials. The researchers plan to recruit 300 eligible patients.
- Conditions
- Stroke, Cerebral Infarction, Brain Infarction, Brain Ischemia
- Trial name
- NCT05068349
- Testing
- Butylphthalide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qianfoshan Hospital
Acute Ischemic Stroke
Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment
Butylphthalide, as a well-known neuroprotective medication, is a family of compounds initially isolated from the seeds of Apium graveolens Linn, of which active ingredient is dl-3-N-butylphthalide (dl-NBP).
- Trial name
- BAST (NCT03539445)
- Testing
- Butylphthalide
- Where
- China
- Volunteers
- 1,216 people
- Sponsor
- Beijing Tiantan Hospital
Breast Cancer, Peripheral Neuropathy
NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy
Phase 2, randomized, double-blind, Placebo-Controlled, Multiple Dose Study for the treatment of Patients with Metastatic Breast Cancer.
- Trial name
- NCT04675450
- Testing
- NBP Softgel Capsules
- Volunteers
- healthy volunteers welcome
- Sponsor
- Conjupro Biotherapeutics, Inc.
Stroke, Transient Ischemic Attack
The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial
The purpose of the study is to evaluate the efficacy and safety of Butylphthalide Soft Capsules (En Bi Pu, NBP) in Secondary Prevention of Ischemic Stroke
- Trial name
- ESCAPE (NCT00724724)
- Testing
- Butylphthalide Soft Capsules, Aspirin
- Where
- 50 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Ischemic Stroke, Minor Stroke
Butylphthalide for Long-term Efficacy in Minor Stroke Study
This study is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the long-term efficacy and safety of butylphthalide in patients with minor acute ischemic stroke (BLESS Trial).
- Trial name
- BLESS (NCT07230587)
- Testing
- Butylphthalide
- Volunteers
- 1,200 people
- Sponsor
- Peking Union Medical College Hospital
Acute Cerebral Stroke Within 12 Hours for the First Time
Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke
The investigators conducted a randomized, double-blind, trial enrolled 60 patients within 12 hours of acute ischemic stroke (AIS) in China.
- Trial name
- NCT02149875
- Testing
- Dl-3-n-butylphthalide, Cerebrolysin
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Shanghai 6th People's Hospital
ST-segment Elevation Myocardial Infarction (STEMI)
A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI
This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether "butylphthalide +PCI" combined treatment mode on the basis of traditional drug therapy…
- Trial name
- RISE (NCT06704685)
- Testing
- Butylphthalide
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Vascular Dementia
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
Butylphthalide soft capsule has been confirmed to have beneficial effects for patients with vascular dementia (VaD) in clinical trial of phase II study.
- Trial name
- NCT03804229
- Testing
- Butylphthalide soft capsule
- Where
- China
- Volunteers
- 707 people
- Sponsor
- Capital Medical University
Vascular Cognitive Impairment no Dementia
The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND
Vascular cognitive impairment no dementia (VCIND) is very common among the aged and tends to progress to dementia, but there have been no proper large-scale intervention trials dedicated to it.
- Trial name
- EBSCPVCIND (NCT02993367)
- Testing
- Butylphthalide Soft Capsules
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Second Hospital of Hebei Medical University
Acute Ischemic Stroke
Butylphthalide for Brain Edema After Endovascular Treatment
This is a prospective, multicenter, randomized controlled clinical study aimed at evaluating the efficacy of butylphthalide in improving the severity of cerebral edema and prognosis in patients with acute anterior circulation…
- Trial name
- NCT07528456
- Testing
- Butylphthalide
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Nanfang Hospital, Southern Medical University